Acute cardiac care & resuscitationCohort study
Clinical Presentation, Shock Severity and Mortality in Patients with De Novo Versus Acute-on-Chronic Heart Failure-Related Cardiogenic Shock
- Observational cohort study
- international
- multicentre
Authors' conclusion
In this large HF-CS cohort, acute-on-chronic HF-CS was associated with more severe CS and higher mortality risk compared to de novo HF-CS, although traditional markers of CS severity and use of treatments were comparable.
Study context
- Population
- Patients with HF-related cardiogenic shock at 16 tertiary care centres in five countries, 2010–2021analysed
- Participants
- 1,030 patients
- Exposure
- Acute-on-chronic HF-CS vs de novo HF-CS
- Acute-on-chronic HF-CSn = 544
- De novo HF-CSn = 486reference
- Outcome
- Mortality
- Follow-up
- 30 days
Main finding
As reported in the abstract
Adjusted hazard ratio
1.38
95% CI 1.10–1.72
P = 0.005
By group
Acute-on-chronic HF-CS vs De novo HF-CS
adjusted HR 1.38 (95% CI 1.10–1.72); P = 0.005
Observational data: associations, not effects.
Further findings
Traditional markers of CS severity (BP, heart rate, lactate) and use of treatments
- Comparable between groups
CS severity
- Acute-on-chronic HF-CS more likely to have higher CS severity
Original publication
Clinical Presentation, Shock Severity and Mortality in Patients with De Novo Versus Acute-on-Chronic Heart Failure-Related Cardiogenic Shock. Eur J Heart Fail. Published 23 November 2023. doi:10.1002/ejhf.3082
Summarised from the published abstract; every number is checked against it